CA2890075C - 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto - Google Patents

7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto Download PDF

Info

Publication number
CA2890075C
CA2890075C CA2890075A CA2890075A CA2890075C CA 2890075 C CA2890075 C CA 2890075C CA 2890075 A CA2890075 A CA 2890075A CA 2890075 A CA2890075 A CA 2890075A CA 2890075 C CA2890075 C CA 2890075C
Authority
CA
Canada
Prior art keywords
compound
alkyl
amino
methyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890075A
Other languages
English (en)
French (fr)
Other versions
CA2890075A1 (en
Inventor
Keqiang Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CA2890075A1 publication Critical patent/CA2890075A1/en
Application granted granted Critical
Publication of CA2890075C publication Critical patent/CA2890075C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2890075A 2012-11-05 2013-11-01 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto Active CA2890075C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722339P 2012-11-05 2012-11-05
US61/722,339 2012-11-05
US201361845399P 2013-07-12 2013-07-12
US61/845,399 2013-07-12
PCT/US2013/067972 WO2014071134A1 (en) 2012-11-05 2013-11-01 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto

Publications (2)

Publication Number Publication Date
CA2890075A1 CA2890075A1 (en) 2014-05-08
CA2890075C true CA2890075C (en) 2021-01-05

Family

ID=50628080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890075A Active CA2890075C (en) 2012-11-05 2013-11-01 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto

Country Status (8)

Country Link
US (3) US9682948B2 (https=)
EP (2) EP2914585B1 (https=)
JP (3) JP6479670B2 (https=)
CN (2) CN107868071B (https=)
AU (3) AU2013337742B2 (https=)
CA (1) CA2890075C (https=)
ES (1) ES2823237T3 (https=)
WO (1) WO2014071134A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
CN107868071B (zh) * 2012-11-05 2021-07-20 爱默蕾大学 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法
MX2020006140A (es) * 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
CN108299367B (zh) * 2018-01-26 2022-04-12 南阳师范学院 一种芹菜苷元氨基甲酸酯类化合物、其制备方法及应用
CA3099311A1 (en) * 2018-05-03 2019-11-07 Georgia State University Research Foundation, Inc. Inhibitors of rsv replication and applications thereof
CN110577532B (zh) * 2018-06-08 2022-06-03 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
WO2020024977A1 (zh) * 2018-08-01 2020-02-06 陕西麦科奥特科技有限公司 用于治疗神经系统疾病的化合物及其应用
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
CN109574975B (zh) * 2019-01-14 2023-07-14 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的晶型及其制备方法和应用
WO2020154434A1 (en) * 2019-01-24 2020-07-30 Pharmatrophix, Inc. Compositions and methods for treating and preventing cognitive dysfunction
CN111825649A (zh) * 2019-04-15 2020-10-27 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的纯化方法
CN114075162A (zh) * 2020-08-20 2022-02-22 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的晶型b及其制备方法、应用
CN112168976B (zh) * 2020-10-15 2022-11-04 天津科技大学 一种黄酮衍生物前药及合成和作为抗肿瘤药物的应用
WO2023288069A1 (en) * 2021-07-15 2023-01-19 Emory University Methods of using substituted flavones for treating bone disorders
CN118251415A (zh) * 2021-10-29 2024-06-25 清华大学 用于治疗或诊断精神分裂症的方法和产品
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações
JP7712994B2 (ja) * 2022-11-02 2025-07-24 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AU2001291077A1 (en) * 2000-09-21 2002-04-02 Teva Pharmaceuticals Industries Ltd. N-disubstituted carbamoyloxy flavones
US20020160983A1 (en) * 2001-03-16 2002-10-31 Alberto Bargiotti Substituted benzopyranones as telomerase inhibitors
CA2442330A1 (en) 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
BRPI0606793A8 (pt) * 2005-02-04 2018-03-13 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
JP5498782B2 (ja) 2006-06-21 2014-05-21 ピラマル エンタープライジーズ リミテッド 増殖性疾患治療用のエナンチオマー的に純粋なフラボン誘導体の調製方法
CZ300589B6 (cs) 2006-09-04 2009-06-24 Univerzita Palackého Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití
WO2010011836A2 (en) 2008-07-25 2010-01-28 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
WO2010107866A2 (en) 2009-03-20 2010-09-23 Emory University Catecholamine derivatives for obesity and neurological disorders
CN101591319B (zh) * 2009-06-22 2011-12-21 复旦大学 黄酮类衍生物及其在制备药物组合物中的用途
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
EP2579870B1 (en) * 2010-06-09 2018-02-14 Emory University Trkb agonists and methods of use
CN107868071B (zh) * 2012-11-05 2021-07-20 爱默蕾大学 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法

Also Published As

Publication number Publication date
EP2914585A4 (en) 2016-03-23
JP6479670B2 (ja) 2019-03-06
US20180186762A1 (en) 2018-07-05
CN107868071B (zh) 2021-07-20
WO2014071134A1 (en) 2014-05-08
EP3369730A1 (en) 2018-09-05
CA2890075A1 (en) 2014-05-08
AU2019213454B2 (en) 2020-07-09
EP2914585A1 (en) 2015-09-09
EP2914585B1 (en) 2018-03-07
CN107868071A (zh) 2018-04-03
AU2013337742A1 (en) 2015-05-21
ES2823237T3 (es) 2021-05-06
AU2019213454A1 (en) 2019-08-29
AU2013337742B2 (en) 2017-11-23
EP3369730B1 (en) 2020-08-05
JP2021050230A (ja) 2021-04-01
CN104812744A (zh) 2015-07-29
JP2019089817A (ja) 2019-06-13
AU2018201060A1 (en) 2018-03-08
US9975868B2 (en) 2018-05-22
US20150274692A1 (en) 2015-10-01
JP2015535290A (ja) 2015-12-10
US10526303B2 (en) 2020-01-07
AU2018201060B2 (en) 2019-05-16
US20170305876A1 (en) 2017-10-26
US9682948B2 (en) 2017-06-20
CN104812744B (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
AU2019213454B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
US20240262840A1 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
US10596145B2 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2020033960A1 (en) Substituted Dihydroxyflavone Derivatives, Compositions, and Methods Related Thereto
HK1259816A1 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
HK1259816B (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
HK40052432B (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
HK40052432A (en) Heterocyclic flavone derivatives, compositions, and methods related thereto

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180731

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025